Acadia Pharmaceuticals Inc
Acadia Pharmaceuticals Inc (ACAD) Options Open Interest
ACAD options open interest is 60,338 contracts. The 2-week average daily volume is 2,563 contracts across the chain.
Read more
Monitoring ACAD open interest helps you see where real money is positioned on Acadia Pharmaceuticals Inc's options and which strikes are attracting the most commitment from traders. Acadia Pharmaceuticals Inc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor ACAD options open interest in real time and find the strikes that matter.
Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising ACAD options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect Acadia Pharmaceuticals Inc to settle.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's.
ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where ACAD open interest is concentrated. Our scanner maps Acadia Pharmaceuticals Inc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade Acadia Pharmaceuticals Inc's options open interest as the signal it is, not as an afterthought.
| 32.00 | 1.45 | 4.60 | 3.03 | 156% | +0.4396 | 5,250 |
| 28.00 | 3.50 | 4.50 | 4.00 | 144% | +0.5553 | 5,023 |
| 27.00 | 3.20 | 6.00 | 4.60 | 151% | +0.5943 | 2,346 |
| 30.00 | 2.05 | 3.50 | 2.78 | 127% | +0.4643 | 2,205 |
| 36.00 | 1.10 | 2.15 | 1.63 | 139% | +0.2979 | 513 |
| 26.00 | 2.80 | 3.90 | 3.35 | 139% | -0.3726 | 5,134 |
| 21.00 | 0.80 | 3.20 | 2.00 | 173% | -0.2127 | 5,010 |
| 20.00 | 0.30 | 1.00 | 0.65 | 118% | -0.1280 | 1,021 |
| 30.00 | 5.80 | 6.60 | 6.20 | 155% | -0.5026 | 135 |
| 23.00 | 1.50 | 2.05 | 1.78 | 130% | -0.2524 | 95 |
As of September 18, 2026
Follow the money
Track ACAD open interest across every strike and expiration, identify where conviction is building, and trade with the positioning data on your side.
Start your 14-day free trial→